Hirobriz Breezhaler: Uses, Dosage & Side Effects

What Is Hirobriz Breezhaler and What Is It Used For?

Hirobriz Breezhaler contains the active substance indacaterol (as indacaterol maleate), a potent and highly selective long-acting beta2-adrenergic agonist (LABA). The medication is formulated as an inhalation powder in hard capsules, each containing 150 micrograms of indacaterol. The capsules are designed exclusively for use with the Breezhaler inhaler device — a dry powder inhaler that punctures the capsule and delivers the fine powder directly to the lungs when the patient inhales through the mouthpiece. This delivery method ensures that the medication reaches the airways where it is needed most, while minimizing systemic absorption and associated side effects.

Indacaterol belongs to the beta2-adrenergic agonist family of bronchodilators, which are among the most widely used and well-studied classes of medications in respiratory medicine. Beta2-adrenergic receptors are found in high density on the smooth muscle cells that surround the airways in the lungs. When indacaterol binds to these receptors, it activates an intracellular signaling cascade involving the enzyme adenylyl cyclase, which increases levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates multiple target proteins responsible for maintaining smooth muscle contraction. The net effect is relaxation of the airway smooth muscle, resulting in bronchodilation — an increase in the diameter of the airways that allows air to flow more freely in and out of the lungs.

What distinguishes indacaterol from short-acting beta2-agonists (SABAs) like salbutamol is its exceptionally long duration of action. A single inhaled dose of 150 micrograms provides clinically significant bronchodilation lasting approximately 24 hours, enabling convenient once-daily dosing. This is achieved through indacaterol's unique pharmacological properties: it has a high affinity for the beta2-receptor and dissociates slowly from the receptor-binding site, which sustains the bronchodilatory signal over a prolonged period. Additionally, indacaterol has a rapid onset of action, with measurable bronchodilation beginning within 5 minutes of inhalation and peak effect occurring within 1 to 4 hours. This combination of fast onset and long duration is relatively unusual among LABAs and is considered a significant clinical advantage.

Hirobriz Breezhaler is indicated specifically for the maintenance treatment of airflow obstruction in adult patients with COPD. Chronic obstructive pulmonary disease is a progressive respiratory condition characterized by persistent airflow limitation that is not fully reversible. It encompasses two main pathological processes: chronic bronchitis (inflammation and narrowing of the bronchial tubes with excess mucus production) and emphysema (destruction of the alveolar walls, leading to reduced gas exchange and air trapping). According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 report, COPD affects an estimated 480 million people worldwide and is the third leading cause of death globally, responsible for approximately 3.2 million deaths annually.

The therapeutic role of Hirobriz Breezhaler in COPD management has been established through extensive clinical trials. The pivotal clinical development program included several large, randomized, double-blind, placebo-controlled and active-comparator studies:

• INHANCE Study: This 26-week trial enrolled 1,683 patients with moderate-to-severe COPD and demonstrated that indacaterol 150 mcg once daily significantly improved trough FEV1 (forced expiratory volume in one second) compared with placebo. The improvement in trough FEV1 at week 12 was approximately 180 mL greater than placebo, exceeding the accepted minimal clinically important difference (MCID) of 100 mL. Indacaterol also demonstrated statistically superior bronchodilation compared with the active comparator tiotropium 18 mcg at several time points.
• INVOLVE Study: This 52-week study in 1,732 patients showed that indacaterol 150 mcg provided sustained bronchodilation over one year, with consistent improvements in lung function, dyspnea scores (as measured by the Transition Dyspnea Index), and health-related quality of life (as measured by the St George's Respiratory Questionnaire). The COPD exacerbation rate was also reduced compared with placebo.
• INLIGHT-2 Study: This 26-week trial compared indacaterol 150 mcg with salmeterol 50 mcg twice daily (an established LABA) and placebo in 1,002 patients. Indacaterol demonstrated statistically superior bronchodilation compared with salmeterol, with a treatment difference in trough FEV1 of approximately 60 mL at 12 weeks, as well as significant superiority over placebo.

Across these trials, patients treated with Hirobriz Breezhaler consistently reported improvements in COPD symptoms including reduced breathlessness, less wheezing, fewer nighttime awakenings, improved exercise tolerance, and better overall quality of life. The medication also reduced the need for rescue short-acting bronchodilator use, an important indicator of symptom control in clinical practice.

Hirobriz Breezhaler was authorized in the European Union in November 2009 by the European Medicines Agency (EMA). It is marketed under several brand names internationally, including Onbrez Breezhaler in many European countries and Arcapta Neohaler in the United States (where it was approved by the FDA in July 2011 at a dose of 75 mcg). The medication is manufactured by Novartis Pharmaceuticals and is available in over 100 countries worldwide. It represents an important option in the GOLD-recommended stepwise approach to COPD pharmacotherapy, where long-acting bronchodilators are the cornerstone of maintenance treatment.

What Should You Know Before Taking Hirobriz Breezhaler?

Contraindications

The primary contraindication to Hirobriz Breezhaler is hypersensitivity (allergy) to the active substance indacaterol or to any of the excipients in the formulation. The capsule contents include lactose monohydrate (which contains trace amounts of milk protein) and magnesium stearate. The capsule shell is made from gelatin. If you have a known allergy to any of these substances, including severe milk protein allergy, you must not use Hirobriz Breezhaler. Patients with galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should also not use this medicine due to its lactose content.

Hirobriz Breezhaler must not be used for the treatment of asthma. The GOLD 2024 guidelines and all major regulatory agencies explicitly state that LABAs should not be used as monotherapy (without an inhaled corticosteroid) in asthma, as this has been associated with an increased risk of asthma-related hospitalizations and death. COPD and asthma require different treatment strategies, and a proper diagnosis should be established before initiating treatment with Hirobriz Breezhaler.

Warnings and Precautions

Before starting Hirobriz Breezhaler, discuss the following conditions and circumstances with your healthcare provider, as they may affect the safety and suitability of this medication:

• Cardiovascular disorders: Beta2-adrenergic agonists can produce cardiovascular effects including increases in heart rate, blood pressure, and cardiac workload. Indacaterol should be used with caution in patients with coronary artery disease, cardiac arrhythmias (particularly tachyarrhythmias), hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm, or other severe cardiovascular disorders. If you experience new or worsening chest pain, palpitations, or an irregular heartbeat while using this medication, contact your doctor promptly.
• QT prolongation: As with other beta2-agonists, indacaterol may cause QTc interval prolongation on electrocardiogram (ECG) at supratherapeutic doses. Use with particular caution in patients with a history of QT prolongation, those taking medications known to prolong the QT interval, and those with electrolyte abnormalities (particularly hypokalemia or hypomagnesemia).
• Thyroid disorders: Beta2-agonists may aggravate thyrotoxicosis (overactive thyroid). Patients with known thyroid disorders should be monitored during treatment.
• Diabetes mellitus: Beta2-agonists can cause transient hyperglycemia (elevated blood sugar) through stimulation of hepatic glycogenolysis. Patients with diabetes should monitor blood glucose levels more closely when starting Hirobriz Breezhaler.
• Seizure disorders: Beta2-agonists may lower the seizure threshold. Patients with epilepsy or a history of seizures should use indacaterol with caution.
• Hypokalemia: Beta2-agonists can cause a dose-related decrease in serum potassium through intracellular redistribution. This effect may be potentiated by concomitant treatment with xanthine derivatives (theophylline), corticosteroids, and diuretics. Clinically significant hypokalemia may increase the susceptibility to cardiac arrhythmias. Monitor potassium levels in patients at risk.

Paradoxical Bronchospasm

As with other inhaled medications, Hirobriz Breezhaler may cause paradoxical bronchospasm — an unexpected tightening of the airways immediately after inhalation that makes breathing more difficult rather than easier. This is a rare but potentially serious adverse reaction. If paradoxical bronchospasm occurs, stop using Hirobriz Breezhaler immediately, use a short-acting rescue bronchodilator, and seek medical attention. Your doctor will reassess your treatment and consider alternative therapies. Do not attempt to use Hirobriz Breezhaler again after an episode of paradoxical bronchospasm unless directed by your physician.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Hirobriz Breezhaler. There are limited data on the use of indacaterol in pregnant women. Animal studies have shown reproductive toxicity at high systemic exposures (delayed ossification and reduced fetal body weight), but these were observed at exposures significantly higher than those achieved with the recommended inhaled dose. As a precaution, Hirobriz Breezhaler should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus. Beta2-agonists can inhibit uterine contractions due to their relaxant effect on smooth muscle, which may affect labor and delivery.

It is not known whether indacaterol is excreted in human breast milk. Indacaterol and its metabolites are excreted in the milk of lactating rats. A risk to the breastfed infant cannot be excluded. The decision to breastfeed during Hirobriz Breezhaler treatment should be made in consultation with your doctor, weighing the benefits of breastfeeding for the infant against the benefits of treatment for the mother.

Driving and Operating Machinery

Hirobriz Breezhaler has no or negligible influence on the ability to drive and use machines. However, dizziness has been reported as an uncommon side effect. If you experience dizziness or other adverse effects that could impair your ability to drive or operate machinery, refrain from these activities until the symptoms resolve.

How Does Hirobriz Breezhaler Interact with Other Drugs?

Indacaterol is metabolized primarily by UDP-glucuronosyltransferase UGT1A1, with a secondary contribution from cytochrome P450 enzyme CYP3A4. It is also a substrate for the P-glycoprotein (P-gp) efflux transporter. These metabolic pathways are relevant for understanding potential drug interactions, particularly with medications that inhibit or induce these enzymes and transporters. However, because Hirobriz Breezhaler is administered by inhalation and systemic bioavailability is relatively low (approximately 43-45% of the nominal dose), the clinical significance of many potential pharmacokinetic interactions is limited.

The following table summarizes the most clinically relevant drug interactions with Hirobriz Breezhaler:

Major Interactions

The most important interaction to be aware of is with other long-acting beta2-agonists (LABAs). Hirobriz Breezhaler must not be used concurrently with other LABA-containing products, whether as single-ingredient formulations (such as salmeterol or formoterol inhalers) or as part of fixed-dose combination inhalers (such as formoterol/budesonide or salmeterol/fluticasone). Concomitant use of two LABAs can lead to an overdose of beta2-adrenergic stimulation, potentially causing tachycardia, tremor, hypokalemia, and serious cardiac arrhythmias. If you are switching from another LABA to Hirobriz Breezhaler, your doctor will instruct you to discontinue the previous LABA before starting the new medication.

Non-selective beta-blockers (such as propranolol and carvedilol) should generally be avoided in patients using Hirobriz Breezhaler, as they can antagonize the bronchodilatory effect and potentially trigger bronchospasm. If beta-blocker therapy is medically necessary, cardioselective beta-blockers (such as bisoprolol or metoprolol) should be preferred, though even these should be used with caution and under close medical supervision.

Minor Interactions

Co-administration with inhaled corticosteroids (ICS) such as budesonide, fluticasone, or beclometasone is not associated with clinically significant pharmacokinetic interactions and is a common and well-established therapeutic combination in COPD management. Similarly, long-acting muscarinic antagonists (LAMAs) such as tiotropium and glycopyrronium can be safely used alongside indacaterol, as the two classes act through different mechanisms to provide complementary bronchodilation. In fact, the fixed-dose combination of indacaterol with glycopyrronium (marketed as Ultibro Breezhaler) has been extensively studied and approved for COPD.

Short-acting bronchodilators, including salbutamol (SABA) and ipratropium (SAMA), can be used as rescue medication alongside regular Hirobriz Breezhaler use without significant interaction concerns. Oral theophylline can be co-administered but requires monitoring of serum potassium levels due to the additive hypokalemic effect.

What Is the Correct Dosage of Hirobriz Breezhaler?

Hirobriz Breezhaler should always be used exactly as your doctor has instructed. The medication comes as hard capsules containing 150 micrograms of indacaterol inhalation powder, which must be administered exclusively through the Breezhaler dry powder inhaler device provided with each pack. The capsules should never be swallowed, as oral ingestion does not achieve therapeutic drug levels in the lungs and the medication is poorly absorbed from the gastrointestinal tract.

Adults

The maximum recommended dose is 150 micrograms once daily. Do not exceed this dose, as higher doses do not provide additional clinical benefit and may increase the risk of adverse effects. The dose should be inhaled at approximately the same time each day to maintain consistent bronchodilation throughout the 24-hour period. Most patients find it convenient to take their dose in the morning, but the specific timing can be adjusted to suit individual routines as long as it remains consistent.

How to Use the Breezhaler Device

Correct inhaler technique is essential for effective drug delivery. The Breezhaler device requires a strong, rapid inhalation to generate sufficient airflow to empty the capsule contents. Follow these steps carefully:

1. Remove the cap: Pull off the cap of the Breezhaler by pulling it upward.
2. Open the mouthpiece: Hold the base of the inhaler firmly and tilt the mouthpiece open.
3. Prepare the capsule: Remove one capsule from the blister pack (peel back the foil, do not push through). Place the capsule in the capsule chamber. Never place a capsule directly in the mouthpiece.
4. Close and pierce: Close the mouthpiece firmly until you hear a click. Hold the inhaler upright and press both side buttons fully in once, then release. You should hear a piercing sound as the capsule is punctured.
5. Exhale completely: Breathe out fully, away from the inhaler. Do not breathe into the mouthpiece.
6. Inhale rapidly and deeply: Place the mouthpiece between your lips and breathe in rapidly, steadily, and as deeply as possible. You should hear a whirring sound as the capsule spins and delivers the powder. If you do not hear a whirring sound, the capsule may be stuck — open the inhaler, gently tap the capsule loose, and try again.
7. Hold your breath: Remove the inhaler from your mouth and hold your breath for at least 5–10 seconds, or as long as is comfortable.
8. Check the capsule: Open the inhaler and check whether powder remains in the capsule. If powder remains, close the mouthpiece and repeat the inhalation steps (steps 5–7). Most capsules are emptied in one or two inhalations.
9. Dispose of the capsule: Once empty, remove and discard the used capsule. Close the mouthpiece and replace the cap.

Children and Adolescents

Hirobriz Breezhaler is not indicated for use in children and adolescents below 18 years of age. COPD is an adult disease, and there is no relevant indication for indacaterol in the pediatric population. Safety and efficacy have not been established in patients under 18 years of age.

Elderly Patients

No dose adjustment is required for elderly patients (65 years and older). Population pharmacokinetic analysis has shown that age does not have a clinically significant effect on indacaterol pharmacokinetics. Clinical trials included a substantial proportion of patients aged 65 and older (approximately 28% of the total study population), and no meaningful differences in safety or efficacy were observed between older and younger patients. However, as with any medication in elderly patients who may have multiple comorbidities, careful monitoring is advisable.

Missed Dose

If you forget to take a dose of Hirobriz Breezhaler, take it as soon as you remember, provided there is still a reasonable interval before the next scheduled dose. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose (two capsules) to make up for a missed dose. Do not use more than one capsule per day. If you miss doses frequently, discuss strategies with your doctor or pharmacist to improve adherence, such as setting a daily alarm or linking inhalation to a consistent daily routine (e.g., after brushing teeth in the morning).

Overdose

If you have used more Hirobriz Breezhaler than prescribed, contact your doctor or seek medical attention. Symptoms of overdose are likely to reflect excessive beta2-adrenergic stimulation and may include tremor, headache, nausea, palpitations, tachycardia (rapid heartbeat), and potentially more serious effects such as cardiac arrhythmias, metabolic acidosis, and hypokalemia. In clinical studies, single doses of up to 3,000 micrograms were administered to healthy volunteers without clinically concerning adverse effects, suggesting a wide safety margin. Treatment of overdose should be symptomatic and supportive. Cardioselective beta-blockers may be considered for severe cardiovascular symptoms, but should be used with extreme caution as they may provoke bronchospasm.

What Are the Side Effects of Hirobriz Breezhaler?

Like all medicines, Hirobriz Breezhaler can cause side effects, although not everybody gets them. The side effects listed below are based on the clinical trial program and post-marketing surveillance data reported to regulatory agencies worldwide. The frequency categories follow the standard convention used in medicine:

Cough After Inhalation

Cough is one of the most characteristic side effects associated with Hirobriz Breezhaler and deserves special mention. In clinical trials, cough occurred in approximately 6-7% of patients receiving indacaterol 150 mcg, compared with approximately 1-2% of patients receiving placebo. The cough is typically mild in intensity, occurs within 15 seconds of inhalation, and lasts for an average of 5-10 seconds (rarely more than a few minutes). It is believed to be caused by the rapid delivery of dry powder to the airways, which stimulates cough receptors in the upper airways. Importantly, this post-inhalation cough is not associated with bronchospasm or worsening of airway obstruction — lung function measurements show that bronchodilation occurs normally despite the cough.

Most patients find that the cough becomes less frequent and less intense over time as they continue regular use. If the cough is particularly bothersome, some practical tips may help: take a sip of water before inhaling, ensure a rapid and deep inhalation technique (a slow inhalation may deposit more powder in the throat), and rinse the mouth with water after inhaling. If the cough persists and is significantly troublesome, discuss it with your doctor, who may consider alternative treatments.

Cardiovascular Effects

As a beta2-adrenergic agonist, indacaterol has the potential to cause cardiovascular effects due to partial cross-reactivity with beta1-adrenergic receptors in the heart. In clinical trials, the incidence of cardiovascular adverse events (including palpitations, tachycardia, and atrial fibrillation) was low and generally comparable between indacaterol and placebo groups. At the recommended dose of 150 mcg, indacaterol has high beta2-selectivity, and clinically significant cardiovascular effects are uncommon. However, patients with pre-existing cardiovascular disease should be monitored, and any new or worsening cardiac symptoms should be reported to a healthcare provider promptly.

When to Seek Medical Attention

Contact your doctor or seek immediate medical attention if you experience any of the following while using Hirobriz Breezhaler:

• Sudden worsening of breathing, wheezing, or chest tightness immediately after using the inhaler (possible paradoxical bronchospasm)
• Signs of a severe allergic reaction: swelling of the face, lips, tongue, or throat; difficulty swallowing; severe rash or hives; difficulty breathing not related to your COPD
• Rapid, pounding, or irregular heartbeat that is unusual or concerning
• Chest pain or tightness that is new or different from your usual symptoms
• Significant muscle weakness, severe muscle cramps, or an irregular heartbeat (possible signs of low potassium levels)

How Should You Store Hirobriz Breezhaler?

Proper storage of Hirobriz Breezhaler is essential to maintain the quality and effectiveness of the medication. Indacaterol inhalation powder is sensitive to moisture, and exposure to humid conditions can cause the powder to clump, reducing the delivered dose and compromising treatment efficacy. Follow these storage guidelines carefully:

• Temperature: Store at temperatures below 30°C (86°F). Do not refrigerate or freeze the capsules.
• Moisture protection: Keep the capsules in the original blister packaging until immediately before use. Each blister strip is designed to protect the capsules from moisture. Do not remove a capsule from its blister until you are ready to inhale it.
• Do not store in the inhaler: Never place a capsule in the Breezhaler device in advance. Only load the capsule into the device at the time of use.
• Replace the inhaler: Each new pack of Hirobriz Breezhaler comes with a new Breezhaler device. Use the new device provided with each prescription refill and dispose of the old one.
• Expiration date: Do not use the capsules after the expiration date printed on the blister and carton. The expiration date refers to the last day of that month.
• Keep out of reach of children: Store the medication in a safe place where children cannot reach it.
• Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

If a capsule has been accidentally exposed to moisture (e.g., left out of the blister overnight in a humid environment), do not use it. Discard the affected capsule and use a fresh one from the blister. If you notice any change in the appearance of the capsule or the powder (such as discoloration, unusual odor, or visible moisture), do not use it and consult your pharmacist.

What Does Hirobriz Breezhaler Contain?

Active Ingredient

The active substance in Hirobriz Breezhaler is indacaterol maleate. Each hard capsule contains indacaterol maleate equivalent to 150 micrograms of indacaterol. Indacaterol is a highly potent, long-acting, selective beta2-adrenergic receptor agonist with a molecular formula of C₂₄H₂₈N₂O₃ (as the free base) and a molecular weight of 392.49 g/mol. The maleate salt form is used to ensure chemical stability and consistent powder characteristics suitable for dry powder inhalation.

Excipients (Inactive Ingredients)

• Lactose monohydrate: This is the primary carrier particle in the formulation. Lactose serves as a bulking agent that allows the fine indacaterol particles to be dispersed efficiently during inhalation. Lactose is derived from milk and contains small amounts of milk protein. Patients with severe lactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not use this product. Those with cow's milk protein allergy should also exercise caution and consult their doctor.
• Magnesium stearate: This is used as a lubricant to improve the flow properties of the powder and to enhance capsule filling during manufacturing.

Capsule Shell

The capsule shell is made from gelatin, which is derived from animal (bovine or porcine) collagen. The capsule is transparent (colorless), allowing visual inspection of the powder contents. The capsules are printed with product identification codes using edible pharmaceutical-grade ink.

Delivered Dose

It is important to understand the distinction between the metered dose and the delivered dose. Each capsule is filled with a metered (nominal) dose of indacaterol maleate equivalent to 150 micrograms of indacaterol. However, the actual amount of drug that reaches the patient's lungs (the fine particle dose or delivered dose) is somewhat less than the nominal dose due to the inherent characteristics of dry powder inhalation. The delivered dose from the Breezhaler mouthpiece is approximately 120 micrograms of indacaterol per actuation. The fine particle dose (particles small enough to penetrate deep into the lungs) is approximately 30-45% of the nominal dose, depending on the patient's inspiratory flow rate. This is why proper inhaler technique with a rapid, deep inhalation is critical for optimal drug delivery.